| Bioactivity | Bebtelovimab a humanized IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19. Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy[1][2]. |
| Name | Bebtelovimab |
| CAS | 2578319-11-4 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Shertel T, et al. Bebtelovimab for Treatment of COVID-19 in Ambulatory Solid Organ Transplant Recipients. Transplantation. 2022 Oct 1;106(10):e463-e464. [2]. Bebtelovimab. IMGT/mAb-DB. |